Savara Inc.
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases.
126 employees · est. 2007 · United States
Savara Inc. is the older company (2007 vs 2009); Savara Inc. is the larger of the two.
Side-by-Side Comparison
| Metric | Savara Inc. | Vicore Pharma AB |
|---|---|---|
| Founded | ||
| Founded | 2007 older | 2009 |
| Headquarters | ||
| Headquarters | United States | Stockholm, Sweden |
| Employees | ||
| Employees | 126 larger | 41 |
| Industry | ||
| Industry | Biopharma, Biotechnology, Pharmaceutical | Biopharma, Biotechnology, Pharmaceutical |
| Funding Stage | ||
| Funding Stage | Post Ipo Equity | Post Ipo Equity |
| Total Funding | ||
| Total Funding | $414.10M | $501.50M |
| Funding Rounds | ||
| Funding Rounds | 15 | 2 |
| Services | ||
| Services | Development of treatments for rare respiratory diseases | Not tracked yet |
| Target Customers | ||
| Target Customers | Patients with autoimmune pulmonary alveolar proteinosis (aPAP) and investors interested in rare disease therapeutics | Not tracked yet |
| Taxonomy | ||
| Taxonomy | Biopharmaceuticals, Rare Respiratory Diseases, Clinical Stage Development, Autoimmune Pulmonary Alveolar Proteinosis, Nontuberculous Mycobacteria Lung Infection, Cystic Fibrosis, Methicillin Resistant Staphylococcus Aureus Lung Infection, Drug Development Partnerships, Orphan Drug Development, Pulmonary Medicine, Indication Expansion, Product Acquisitions, Antibacterial Activity, Drug Delivery, Rare Disease Therapeutics | Pharmaceutical Company, Clinical-stage, Respiratory Diseases, Idiopathic Pulmonary Fibrosis, ATRAG, Phase 2a Development, Digital Therapeutic, Breakthrough Device Designation, Drug Development, Orphan Drug Designation, Rare Diseases, Nasdaq Stockholm, Astra Zeneca, Bioventurehub, Innovative Medicines |
| Website | ||
| Website | savarapharma.com | vicorepharma.com |
About Savara Inc.
Savara Inc. is a clinical stage biopharmaceutical company specializing in rare respiratory diseases. Their lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) currently in Phase 3 development for autoimmune pulmonary alveolar protein...
About Vicore Pharma AB
Vicore Pharma AB is a Swedish biopharmaceutical company founded in 2009 that focuses on developing drugs with disease-modifying potential for respiratory diseases. It is currently advancing Buloxibutid (C21), the first-in-class orally available small molecule angiotensin II type 2 receptor agonist,...
We will tell you when either one moves
BounceWatch watches Savara Inc. and Vicore Pharma AB for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Savara Inc. and Vicore Pharma AB — by email.
Frequently Asked Questions
Compare Savara Inc. with someone else
Start typing a company name or domain.
Related Comparisons
Compiled from the BounceWatch company index. We last looked at Savara Inc. on 23 Mar 2025, and Vicore Pharma AB on 11 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.